Lupin Ltd — Board/Management Information 2022

Dec 8, 2022

==> picture [79 x 93] intentionally omitted <==

December 8, 2022

 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001.

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).

We are pleased to enclose a Press Release as regards, appointment of Mr. Spiro Gavaris as President of U.S. Generics business of the Company.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

Rajvardhan

Vishnu Satam

Digitally signed by Rajvardhan Vishnu Satam DN: c=IN, st=Maharashtra, 2.5.4.20=c19d8ef961d9fa59e973a093a4d3924b2532eb2f496ea7e2 abcf74700f5375b7, postalCode=400104, street=2404,SEJAL TOWER,SEJAL PARK,LINK ROAD,GOREGAON WEST,Mumbai,Motilal Nagar,Borivali,Mumbai Suburban, pseudonym=9a4b7cd219ea516ad56e6d651dcbbe5b, title=0191, serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f726c db67a2ff09c4242771b2a, o=Personal, cn=Rajvardhan Vishnu Satam Date: 2022.12.08 18:22:40 +05'30'

R. V. SATAM COMPANY SECRETARY (ACS - 11973)

Encl: a/a

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

Press Release

==> picture [67 x 70] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

Lupin Appoints Spiro Gavaris as President of U.S. Generics Business

Mumbai, Baltimore, December 08, 2022 : Global pharma major Lupin Limited (Lupin) today announced the appointment of Spiro Gavaris as President U.S. Generics business. As part of Lupin’s senior leadership team, Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business.

Spiro joins Lupin with significant experience in the branded, generic and biotech industries. He most recently served as President of Specialty Generics business at Mallinckrodt Pharmaceuticals and the President of US Injectables at Hikma.

Commenting on the appointment, Vinita Gupta, CEO, Lupin said, “Spiro brings strong pharma and biotech experience and has an established track record of success in building generics business across platforms, and in particular on the injectables front. We are delighted to welcome him to our leadership team.”

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue on research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information. Follow us on Twitter: https://twitter.com/LupinGlobal LinkedIn: https://www.linkedin.com/company/lupin Facebook: http://www.facebook.com/LupinWorld/

For further information or queries please contact –

Shweta Munjal

Vice President & Global Head – Corporate Communications Email: shwetamunjal@lupin.com

Page 1 of 1